Taysha Gene Therapies, an early stage biotech developing AAV-based gene therapies for CNS disorders, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Founded ...
CNS Pharmaceuticals has filed to raise $9.6 million from an IPO. The firm is developing Berubicin, a compound for the treatment of brain tumors. While I wish CNSP well, the IPO has no investor support ...
45 clinical trial sites of the 60 sites selected across the U.S., Italy, France, Spain, and Switzerland open and enrolling patients HOUSTON, TX / ACCESSWIRE / May 25, 2023 / CNS Pharmaceuticals, Inc. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback